Autopsy report · NCT03661047

OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer

“Study will be closed due to zero enrollment in over 2 years.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Massachusetts General Hospital

Sponsor type

University, hospital or other

Conditions

Colon Cancer

Interventions

AMR101 (VASCEPA, icosapent ethyl)

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Reconstruction Flaps for Nasal Surgical Wounds RCT
  “Study closed before enrollment could begin.” (80% match in meaning)
• Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
  “No participants enrolled for more than two years. No plan to continue study.” (80% match in meaning)
• Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
  “Study closed before total enrollment met.” (79% match in meaning)
• Adipose Derived SVF for Aero-digestive & Enterocutaneous Fistulae
  “Study closed due to lack of patient enrollment.” (78% match in meaning)
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
  “Study closed to enrollment due to low accrual.” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.